Form 4: Mirum Pharmaceuticals CEO Christopher Peetz Sells Shares to Cover Tax Obligations

Mirum Pharmaceuticals CEO Christopher Peetz sold 5,159 shares of common stock on January 9, 2023, to cover tax withholding obligations associated with the vesting of restricted stock units.

Summary

• On January 9, 2023, Christopher Peetz, CEO of Mirum Pharmaceuticals, sold 5,159 shares of common stock at a price of $20.6223 per share.
• The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units.
• Following the transaction, Peetz directly owns 91,953 shares of Mirum Pharmaceuticals common stock.
• Peetz also indirectly owns 208,570 shares through The Peetz Family Trust.
• An adjustment was made to correct a previous reporting error where 7,000 shares held indirectly were incorrectly reported as direct holdings.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock sale for tax purposes. It doesn't inherently indicate positive or negative sentiment about the company's future, but insider sales can sometimes be perceived negatively by the market.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to track executive sentiment and potential alignment with company performance. These filings are closely watched in the pharmaceutical industry to gauge executive confidence and potential strategic shifts.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are common across the pharmaceutical industry.
• Comparing Peetz's transactions to those of CEOs at similar-sized biotech firms like BioCryst Pharmaceuticals or Travere Therapeutics would provide context on the scale and frequency of such sales.
• For example, if other CEOs in the sector are also selling shares to cover taxes after RSU vesting, it suggests a standard practice rather than a specific concern about Mirum's prospects.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders if it creates downward pressure on the stock price, although sales for tax purposes are generally understood.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates